TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14747047
Drug: Androgen blockade
Normalized name: Blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen blockade with 4 cycles of immediate chemotherapy
Study: 14747047
Drug: Androgen blockade
Normalized name: Blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen blockade with delayed chemotherapy
Study: 11109313
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy (HRT) with 17-beta-estradiol and noretisterone acetate, TTS for 3 months.
Study: 3313739
Drug: Mefloquine 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 750 mg, sulfadoxine 1500 mg and pyrimethamine 75 mg (MSP) single oral dose
Study: 3313739
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg/kg tds X 7 days oral therapy)
Study: 27327024
Drug: High-CHO (HCHO):
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-CHO (HCHO): 10 g·kg CHO, 2.5 g·kg protein, and 0.8 g·kg fat for the entire trial period
Study: 27327024
Drug: Reduced-CHO but
Normalized name: trans-but-2-enedioic acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-CHO but high-fat availability (HFAT): 2.5 g·kg CHO, 2.5 g·kg protein, and 3.5 g·kg fat for the entire trial period
Study: 24293578
Drug: 7.5 mg/day
Normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/day of prednisolone for 6 weeks
Study: 18801638
Drug: Current therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapy for cardiac arrest (not specified as intervention or control)
Study: 7867183
Drug: c7E3 Fab
Normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: c7E3 Fab 0.25 mg/kg
Study: 2026760
Drug: Insulin dose
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dose 0.6 mU/kg‐min
Study: 2026760
Drug: Insulin dose
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dose 5.0 mU/kg‐min
Study: 25828994
Drug: Concurrent anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent anemia and inflammation (CRP ≥ 10 mg/L)
Study: 23713032
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug) during PEI after leg cycling
Study: 23713032
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug) during PEI after handgrip
Study: 19351238
Drug: Ciclesonide therapy
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide therapy
Study: 8098276
Drug: Denopamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denopamine (20 mg)
Study: 2957943
Drug: Intrahepatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrahepatic therapy (14-day continuous infusion of fluorodeoxyuridine at 0.3 mg/kg body weight per day)
Study: 2957943
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy (14-day continuous infusion of fluorodeoxyuridine at 0.15 mg/kg body weight per day)
Study: 2957943
Drug: Crossover from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover from systemic to intrahepatic therapy after tumor progression
Study: 2957943
Drug: Intrahepatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrahepatic therapy
Study: 28753030
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture and normal saline injections
Study: 28753030
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with anti-parkinsonian drugs
Study: 25678098
Drug: Finerenone (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone (doses ranging from 2.5 to 20.0 mg once daily)
Study: 25678098
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg every second day to 50 mg once daily for 90 days)
Study: 10562113
Drug: Advanced nurse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced nurse practitioner intervention in cardiovascular medicine
Study: 8804228
Drug: Vasoactive agents
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive agents (dopamine)
Study: 1832181
Drug: Antacids and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids and H2-antagonists
Study: 6859790
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydrochlorothiazide and metoprolol
Study: 26550687
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol 100/25 μg
Study: 25155600
Drug: Eltrombopag (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (200 mg single dose)
Study: 25155600
Drug: Boceprevir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir (800 mg every 8 hours for 10 days)
Study: 25155600
Drug: Telaprevir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telaprevir (750 mg every 8 hours for 10 days)
Study: 25155600
Drug: Eltrombopag (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (200 mg single dose with boceprevir or telaprevir)
Study: 20511481
Drug: Gabapentin enacarbil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin enacarbil, 1200 mg
Study: 18794746
Drug: Individualized physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized physical therapy and exercise, standardized self-training program, and back education
Study: 18794746
Drug: Self-training program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-training program and back education (no individualized therapy)
Study: 12271286
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod 5% cream, applied 3 times a week for up to 16 weeks
Study: 7852871
Drug: Purified fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified fibrinogen from insulin-dependent diabetics
Study: 24947106
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of responsive stimulation and enhanced nutrition
Study: 23673269
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) infusion
Study: 23673269
Drug: EP4 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP4 receptor antagonist BGC20‐1531
Study: 23673269
Drug: Prostaglandin F2α
Normalized name: 15(S)-15-Methyl Prostaglandin F2α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2α (PGF2α) infusion
Study: 20827017
Drug: Hydrocortisone aceponate
Normalized name: HYDROCORTISONE ACEPONATE
DrugBank: Hydrocortisone aceponate (DB14538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone aceponate (0.127%) lipophilic cream applied twice daily
Study: 18221398
Drug: GHRH +
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH + ARG (1 microg/kg body weight i.v. GHRH followed by 0.5 g/kg body weight i.v. arginine hydrochloride)
Study: 12513038
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate daily
Study: 9204355
Drug: Iopentol (Imagopaque
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopentol (Imagopaque 250 mg I/ml)
Study: 9204355
Drug: Diatrizoate (Urografin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diatrizoate (Urografin 219 mg I/ml)
Study: 8201703
Drug: Intraarterial thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial thrombolytic therapy (urokinase)
Study: 2444000
Drug: Cefazolin (CFZ)
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin (CFZ) 4 days (16 X 0.5 g)
Study: 2444000
Drug: Cefuroxime (CFX)
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime (CFX) 2 days (4 X 1.5 g)
Study: 2444000
Drug: Cefazolin (CFZ)
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin (CFZ) 1 day (4 X 0.5 g)
Study: 1146747
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives with vitamin B6 deficiency
Study: 30396006
Drug: Barley beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barley beta glucans (6 g in experimental bread)
Study: 3071871
Drug: Endoscopic haemostatic
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic haemostatic injection with absolute alcohol (Asaki's method)
Study: 2651100
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (blood transfusions, antacids, cimetidine, pirenzepine)
Study: 27922030
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg, before bedtime)
Study: 25524481
Drug: Low viscosity
Normalized name: Gentamicin low viscosity bone cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low viscosity bone cement (group L)
Study: 22803642
Drug: TAK-683 (0.01-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-683 (0.01-2.0 mg)
Study: 22803642
Drug: TAK-683 (0.03-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-683 (0.03-1.0 mg on day 1, followed by 0.01-2.0 mg continuous infusion on days 2-13)
Study: 22803642
Drug: TAK-683 (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-683 (2.0 mg day(-1) continuous dosing)
Study: 22803642
Drug: TAK-683 continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-683 continuous dosing
Study: 16447105
Drug: Gentamicin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (2.5 mg/kg intramuscularly every 12 h for 7 days)
Study: 16447105
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg orally for adults and 2.2 mg/kg orally for children every 12 h for 7 days)
Study: 1738926
Drug: ALG (Merieux)
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALG (Merieux) until serum creatinine was less than 300 mumol/L
Study: 1738926
Drug: Steroid-sensitive rejection
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-sensitive rejection
Study: 1738926
Drug: Steroid-resistant rejection
Normalized name: Tumor rejection antigen AB
DrugBank: Tyrosinase (DB16626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-resistant rejection
Study: 1738926
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year SCr for patients with steroid-sensitive rejection
Study: 1738926
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year SCr for patients with steroid-resistant rejection
Study: 30502047
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg daily plus P2Y12 inhibitor monotherapy (Group 1)
Study: 30502047
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT) (Group 2)
Study: 30502047
Drug: Standard-of-care vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care vitamin K antagonist and DAPT (Group 3)
Study: 28447159
Drug: Short-term adjunctive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term adjunctive antiarrhythmic drug therapy with amiodarone (group A) for the first 3 months
Study: 28447159
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic drug therapy except for beta blockers (group B)
Study: 28447159
Drug: Short-term adjunctive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term adjunctive antiarrhythmic drug therapy with amiodarone (group A)
Study: 27515716
Drug: FPG of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG of 5.5-6.9mmol/L
Study: 25060541
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate (FF) 9.6 μg MDI
Study: 25060541
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate (FF) 2.4 μg MDI
Study: 25060541
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate (FF) 4.8 μg MDI
Study: 25060541
Drug: Foradil (FA)
Normalized name: formoterol fumarate Inhalation Powder [Foradil]
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Foradil (FA) 12 μg
Study: 23209840
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment (BACs of 0.048%)
Study: 23209840
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment (BACs of 0.082%)
Study: 23209840
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment (BACs of 0.10%)
Study: 23209840
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment (BACs of 0.00%)
Study: 20833874
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (suture repair of the injured ligament(s) within the first week after injury, followed by a below‐the‐knee plaster cast for six weeks with full weight‐bearing)
Study: 20833874
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment (use of an Aircast ankle brace for three weeks)
Study: 16416642
Drug: Restylane 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane 0.7 mL
Study: 16416642
Drug: Hylaform 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylaform 1.0 mL
Study: 2239757
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 40% medium-chain triglycerides and added L-carnitine
Study: 2239757
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 40% medium-chain triglycerides without added L-carnitine
Study: 31444180
Drug: MRI-based active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-based active surveillance protocol with standardised triggers for repeated biopsies and radical treatment
Study: 27509703
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment and aspiration of abscess cavity
Study: 21943067
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle modification advice (3-monthly)
Study: 21943067
Drug: Less-intensive lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-intensive lifestyle modification advice (12-monthly; control group)
Study: 18280963
Drug: Separate consultation
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate consultation with an oral and maxillofacial surgeon before surgery
Study: 17161066
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (PCI)
Study: 12749435
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (12.5 mg/d for the first 10 days of the cycle)
Study: 30225967
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg/d)
Study: 1331443
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg once daily for four weeks
Study: 1331443
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg once daily for four weeks
Study: 1331443
Drug: Lisinopril 10-20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10-20 mg once daily for six weeks
Study: 3904570
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium 50 mg tid
Study: 12118026
Drug: Irinotecan (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (350 mg/m² intravenously for 90 minutes) alone
Study: 12118026
Drug: Irinotecan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (100 mg/m²) with ketoconazole (200 mg orally for 2 days)
Study: 12118026
Drug: Irinotecan (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (350 mg/m²) alone
Study: 8710065
Drug: rIFNA (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFNA (9 million IU intramuscular every other day for 6 months)
Study: 1495453
Drug: Desmopressin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (oral administration)
Study: 17327245
Drug: Albendazole (three-monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (three-monthly from age 15 months to 5 years)
Study: 17327245
Drug: Placebo (three-monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three-monthly from age 15 months to 5 years)
Study: 11907491
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg almotriptan
Study: 31871115
Drug: Atezolizumab (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (one dose prior to cisplatin CRT, followed by two doses during CRT)
Study: 31871115
Drug: Atezolizumab (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (three doses during CRT)
Study: 30134301
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 mg, orally) administered the night before surgery and 2 hours before anesthesia induction
Study: 30134301
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 mg, orally)
Study: 28490565
Drug: ipragliflozin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipragliflozin (50 mg daily)
Study: 28490565
Drug: metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (1000 mg daily)
Study: 26062822
Drug: Iterative Bayesian
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iterative Bayesian PK-guided dosing
Study: 26062822
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing procedure
Study: 18575077
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of telmisartan and ramipril
Study: 9566654
Drug: Movement and
Normalized name: Centrum Movement and Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement and swimming program (swimming sessions twice weekly and group physical activity once weekly, each lasting 30 minutes for 6 months)
Study: 9566654
Drug: Bobath physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bobath physical therapy (30 minutes, 4 days per week)
Study: 25955225
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg) and calcitriol adjusted to achieve iPTH < 300 pg/mL
Study: 23070071
Drug: Cisplatin (CDDP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (CDDP), 20 mg/m × 5 days every 21 days (arm A)
Study: 23070071
Drug: Cisplatin (CDDP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (CDDP), 40 mg/m per week (arm B)
Study: 20032478
Drug: Quercetin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 150 mg/d
Study: 2974769
Drug: Domperidone (DA2-antagonist)
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (DA2-antagonist) with ANP infusion
Study: 2974769
Drug: Domperidone (DA2-antagonist)
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (DA2-antagonist) with head-down tilt
Study: 2974769
Drug: ANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP infusion
Study: 30307945
Drug: Protein-calorie supplement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-calorie supplement (PCS) plus micronutrient supplement (MNS)
Study: 30307945
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement (MNS) alone
Study: 28012242
Drug: Nonivamide (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonivamide (0.15 mg per day in 450 mL of a milk shake)
Study: 26602097
Drug: Cancer vaccine
Normalized name: Hyperacute pancreatic cancer vaccine
DrugBank: Algenpantucel-L (DB17184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer vaccine prepared from autologous dendritic cells and uveal melanoma RNA
Study: 23177917
Drug: Office administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office administration of mifepristone
Study: 21598413
Drug: Panax ginseng
Normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax ginseng extract (20 g/day mixed with 200 ml of water, three times/day for seven days prior and four days after exercise)
Study: 18283204
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of oral glucosamine sulfate once daily
Study: 16571285
Drug: SFI pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFI pre-treatment with GP regimen